BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...
BioCentury | Aug 29, 2019
Distillery Therapeutics

MLANA-loaded nanoparticle vaccine plus mAbs against PD-1 and OX40 to sensitize melanoma to Imbruvica

DISEASE CATEGORY: Cancer INDICATION: Melanoma Immunization with an MLANA-loaded nanoparticle vaccine in combination with mAbs against PD-1 and OX40 could sensitize melanomas to Imbruvica ibrutinib. The vaccine consists of polylactic-co-glycolic acid polymer nanoparticles loaded with...
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

Tscan is screening TCRs against a genome-wide library of antigens to systematically identify novel cancer targets for T cell therapies that avoid off-target toxicities. "Most targets have been discovered in a one-off fashion, notably by...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
BioCentury | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the...
BioCentury | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020. In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent...
Items per page:
1 - 10 of 115